Last updated on January 2020

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk


Brief description of study

The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.

Clinical Study Identifier: NCT03730662

Find a site near you

Start Over

City Hospital of Saint Martyr Elizabeth

Saint Petersburg, Russian Federation
  Connect »

Medical Military Academy

Saint Petersburg, Russian Federation
2.61miles
  Connect »

City Consultative and Diagnostic Center

Saint-Petersburg, Russian Federation
7.22miles
  Connect »

SPb GUZ "Diagnostic Center #85"

Saint Petersburg, Russian Federation
7.29miles
  Connect »